BioSpace News Archive

Drug Development

Promising 2-year updated data from cadonilimab presented at 2023 ASCO highlighting promising efficacy in PD-L1-negative patients

Akeso, Inc. (9926.HK) (“Akeso”) released two-year updated data from a Phase Ib/II clinical study of cadonilimab – a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso – in combination with chemotherapy as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 6, 2023
·
4 min read
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 11:20 a.m. PDT (7:20 p.m. BST).

June 6, 2023
·
1 min read
Business

Kallyope Appoints Franz Humer, Ph.D., as Chair of its Board of Directors

Kallyope, Inc. today announced the appointment of Franz Humer, Ph.D., a distinguished global industry leader in the life sciences, finance, and investment, as the new chair of its board of directors.

June 6, 2023
·
3 min read
Drug Development

BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme

BPGbio, Inc today announced that patients have been initially dosed in its Phase 2 trial for BPM 31510 for Glioblastoma Multiforme (GBM), a fast-growing and aggressive form of brain cancer.

June 6, 2023
·
3 min read
Drug Development

Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors

Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors.

June 6, 2023
·
6 min read
Business

Theralase(R) Announces Appointment of New Independent Director

Theralase Technologies Inc. is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc.

June 6, 2023
·
7 min read
RxLightning Closes $17.5M Series A to Accelerate Growth and Remove Barriers to Essential Specialty Medications

RxLightning today announced that it closed a $17.5 million Series A investment to support the company’s growth and further remove barriers to life-saving therapies.

June 6, 2023
·
5 min read
Drug Development

Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp. today announced the completion of dosing of all participants of the placebo-controlled EXCELLENCE Phase 2/3 study ANAVEX®2-73-RS-003 in pediatric patients with Rett syndrome.

June 6, 2023
·
6 min read
Biotech Beach

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

CalciMedica Inc. today announced the publication of preclinical data in TheJournal of Clinical Investigation (JCI) Insight that details the potential benefit of CRAC channel inhibitors for chronic pancreatitis (CP).

June 6, 2023
·
5 min read
Pharm Country

Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

Intensity Therapeutics, Inc. today announced that data from its INVINCIBLE study was presented on June 4, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago and virtually from June 2-6, 2023.

June 6, 2023
·
9 min read